Imatinib’s initial approval was for CML, characterized by the presence of the Philadelphia chromosome, a molecular juxtaposition of the tyrosine kinase ABL1 on chromosome 9 to BCR on chromosome 22 (12). The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.